↓ Skip to main content

Dove Medical Press

Article Metrics

Role of zoledronic acid in the prevention and treatment of osteoporosis

Overview of attention for article published in Clinical Interventions in Aging, May 2014
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
30 Dimensions

Readers on

mendeley
86 Mendeley
Title
Role of zoledronic acid in the prevention and treatment of osteoporosis
Published in
Clinical Interventions in Aging, May 2014
DOI 10.2147/cia.s7282
Pubmed ID
Authors

Agnès Räkel, Andrée Boucher, Louis-Georges Ste-Marie

Abstract

Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced osteoporosis. Given that Zol is generally well tolerated and very convenient, it is an interesting therapeutic option for aging patients who take multiple oral drugs, who have adherence or gastrointestinal tolerance issues, and who have an indication for oral bisphosphonates. Zol is not recommended for patients with severe renal impairment. Vitamin D deficiency should be corrected before the administration of Zol.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 86 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Unknown 85 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 12 14%
Student > Bachelor 12 14%
Student > Master 11 13%
Other 10 12%
Researcher 9 10%
Other 16 19%
Unknown 16 19%
Readers by discipline Count As %
Medicine and Dentistry 34 40%
Biochemistry, Genetics and Molecular Biology 11 13%
Agricultural and Biological Sciences 6 7%
Engineering 6 7%
Pharmacology, Toxicology and Pharmaceutical Science 4 5%
Other 7 8%
Unknown 18 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2014.
All research outputs
#3,003,313
of 3,750,359 outputs
Outputs from Clinical Interventions in Aging
#456
of 521 outputs
Outputs of similar age
#76,474
of 96,044 outputs
Outputs of similar age from Clinical Interventions in Aging
#57
of 59 outputs
Altmetric has tracked 3,750,359 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 521 research outputs from this source. They receive a mean Attention Score of 3.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 96,044 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.